A new phase II/III clinical trial will further investigate the effectiveness of the lung cancer vaccine tergenpumatucel-L (HyperAcute-Lung immunotherapy, or HAL) against non-small cell lung cancer (NSCLC). Patients with advanced NSCLC that has resisted previous treatment will receive either HAL or the chemotherapy drug docetaxel (Taxotere). HAL consists of lung cancer cells that have been modified to prevent them from growing. A mouse gene has been inserted into these cells, causing them to express a molecule on their surface that human immune systems recognize as foreign. When the cells are injected into humans, they provoke a strong immune response, which stimulates the immune system to also attack the patient’s own lung cancer cells. A previous phase I/II trial of HAL had produced promising results.